– Approved label for TOMI’s BIT™ validates claims for its effectiveness in addressing some of the most harmful
pathogens* in hospitals; C. diff+, MRSA**and H1N1** –
– Significantly expands opportunity with California healthcare networks –
BEVERLY HILLS, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (OTC Pink: TOMZ) (TOMI), a global bacteria decontamination and infection prevention company, announced it received
an amended label for its Binary Ionization Technology (BIT™) from the California Department of Pesticide Regulation in addition to
the United States Environmental Protection Agency (EPA) registered label. The amended label approves the addition of specific
claims against the organisms Clostridium difficile spores (C.diff)+, Methicillin Resistant Staphylococcus aureus
(MRSA)**and influenza (H1N1)**, enabling TOMI to directly market such claims to healthcare
networks across California.
Dr. Halden Shane, TOMI’s Chief Executive Officer, stated: “This most recent amendment to our EPA label unlocks a significant
market opportunity in the California healthcare industry as we are now able to specifically market our SteraMist BIT platform to
some of the largest healthcare networks in the state. The amendment also provides further validation of our technology as we
underwent significant testing to demonstrate BIT’s efficacy against the pathogens* identified in our label –
MRSA**, H1N1** and C. diff spores+. The value proposition of our SteraMist platform goes beyond
the health and safety benefits it provides in disinfecting indoor space and surfaces; it also provides hospitals and healthcare
facilities with a simple, quick and cost effective solution to reducing penalties associated with the Affordable Care Act and
Medicare’s non-payment policy, which could lead to better risk management and outcomes.
“We are very excited about the new opportunities in the California hospital and healthcare market. We are beginning to rollout a
comprehensive marketing campaign to build our presence within this lucrative market. We look forward to keeping you updated on our
progress,” concluded Dr. Shane.
TOMI received its initial EPA registration (no. 90150-2) for BIT in June 2015, for use as a healthcare-hospital disinfectant.
Its label was amended in February 2016 to include its effectiveness in disinfecting Clostridium difficile (C. diff)
spores+, Methicillin Resistant Staphylococcus aureus (MRSA) **, Pseudomonas* and
influenza (H1N1) **, which are three of the most prevalent, harmful and costly pathogens facing healthcare
systems worldwide. TOMI’s SteraMist BIT is currently registered in 49 states to date. The SteraMist BIT brand of products includes
the SteraMist Surface Unit, which is a handheld, point-and-spray application, and SteraMist Environment System, which is a complete
room fogging system. More information on TOMI’s complete suite of SteraMist BIT products can be found at www.tomimist.com or below.
Source Materials
+Clostridium difficile spores (C. diff) (ATCC# 43598) test
conducted with SteraMist™ Environment System.
** Methicillin Resistant Staphylococcus aureus (MRSA), Pseudomonas and influenza
(H1N1) test conducted with SteraMist Surface Unit.
* Pathogens: SteraMist disinfects against Clostridium difficile spores (C. diff) (ATCC# 43598),
Methicillin Resistant Staphylococcus aureus (MRSA) (ATCC# 33592), and Influenza A (H1N1) virus (ATCC VR-1469).
About TOMI™ Environmental Solutions, Inc.
TOMI™ Environmental Solutions, Inc. (OTC Pink: TOMZ) is a global bacteria decontamination and infectious disease control company, providing
eco-friendly environmental solutions for indoor surface decontamination through manufacturing, sales and licensing of our premier
platform of Hydrogen Peroxide based products that uses Binary Ionization Technology® (BIT™) , a state of the art
technology for the production of its six-log mist represented by the TOMI™ SteraMist™ brand.
TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities,
cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing
facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and
multi-unit residences.
TOMI also develops training programs and application protocols for its clients and is a member in good standing with The
American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection
Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality
Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we
expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,”
“projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements
addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including
statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements
within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors
that could cause our actual results to differ materially from our anticipated results. The information provided in this document is
based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements
after the date of this release.
INVESTOR RELATIONS CONTACT:
Becky Herrick & Kirsten Chapman
LHA Investor Relations
(415) 433-3777
tomi@lhai.com
MEDIA RELATIONS CONTACT:
Aaron Loveland
VP of Marketing and Public Affairs
(240) 672-6263
aloveland@tomimist.com
